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arms were compared: cohort A patients (high-risk) treated by either TAVR (n149) or
surgical aortic valve replacement (SAVR, n138); and cohort B patients (considered
inoperable) treated by either TAVR (n72) or medical therapy only (MedTx, n95).
Results: In the total group of patients included in the PARTNER trial who underwent
TAVR, those having no COPD (n1096) and non-O2-dep COPD (n627) had better
1-year survival than did O2-dep COPD patients (n215). (Table) O2-dep COPD patients
who underwent TAVR and survived for 1 year had relatively low rates of high functional
class (NYHA class I/II): 79.2% of cohort A patients; 52.4% of cohort B. There were no
differences in baseline characteristics between the TAVR and control groups in the
different subgroups evaluated. In cohort A patients, 1-year outcomes did not differ
significantly between TAVR and SAVR. In cohort B patients, TAVR, compared to
MedTx, improved 1-year survival free of hospitalization but not 1-year survival. (Table)
Conclusions: Patients with severe COPD and severe AS are at higher risk for worse
clinical outcome and lower survival. In COPD patients, TAVR had better outcome than
did medical therapy but showed no benefit over SAVR.
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Background: The PARTNER Trial demonstrated that transcatheter aortic valve replace-
ment (TAVR) in high surgical risk patients with aortic stenosis was non-inferior to
surgical AVR. Whether there are gender-specific differences in the application of TAVR
to this high-risk population are unknown.
Methods: Patients enrolled in the high-surgical risk cohort of the PARTNER Trial
(Cohort A) were included in this analysis (n697). Gender-specific differences in baseline
characteristics and outcomes at 2 years of follow-up were compared by randomized
treatment assignment.
Results: Despite greater age (84.9 vs. 83.4, p0.01), and slightly higher median STS
scores (11.1 vs. 11.0, p0.03), women (n298) had a lower prevalence of important
comorbidities, including diabetes (35.6% vs. 45.6%, p0.01), smoking history (33.2% vs.
60.7%, p0.001), coronary artery disease (64.4% vs. 83.7%, p0.001), prior CABG
(19.8% vs. 60.4%, p0.001), peripheral vascular disease (36.4% vs. 46.9%, p0.01), and
chronic kidney disease (11.7% vs. 23.9%, p0.001). There were no differences in
outcomes at 30 days between TAVR and surgery in women; among TAVR patients, there
were similar rates of both mortality (4.1% vs. 3.0%, p0.58) and stroke (5.5% vs. 4.0%,
p0.52) in women compared to men. Compared to surgery, women undergoing TAVR
had better one (18.5% vs. 29.5%, p0.02) and 2-year (28.6% vs. 38.6%, p0.05)
survival, whereas, among men, there was no difference at either one (28.5% vs. 25.2%,
p0.67) or 2 years (37.5% vs. 32.1%, p0.43). Compared to surgery, women undergoing
TAVR had higher stroke rates at 1 year (7.1% vs. 0.7%, p0.01); this difference was not
seen in men (5.3% vs. 5.0%, p0.90). There was a significant treatment-gender
interaction for mortality and stroke at 1 but not 2 years, with no significant interactions for
other outcomes.
Conclusions: Gender-specific differences in outcomes (beyond 30 days) were observed
among randomized patients in PARTNER suggesting TAVR may be the preferred
therapy among women. Further investigation is required to determine whether this benefit
can be attributed specifically to gender, or whether other factors may be involved.
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Background: Female sex is associated with adverse outcomes following conventional
aortic valve replacement. We investigate gender differences following transcatheter aortic
valve implantation (TAVI) in the UK’s National Institute for Cardiovascular Outcomes
Research (NICOR) TAVI Registry.
Methods: Retrospective analysis of 1627 patients enrolled in a UK multicentre registry
from January 2007 to December 2010. TAVI was conducted via transfemoral, transapical,
subclavian/transaxillary and transaortic access routes with implantation of Medtronic
CoreValve ReValving System®, Edwards SAPIENTM and SAPIEN XTTM devices.
Results: TAVI was performed in 756 (46.5%) females and 871 (53.5%) males aged
82.66.8 years and 80.87.6 years respectively. Females had a higher peak aortic
gradient (84.428.6mmHg v 76.624.5mmHg; p0.001) and smaller aortic annulus
diameter (21.12.8mm v 23.03.1mm; p0.001). Men had greater prevalence of type
II diabetes (23.9% v 19.2%; p0.021), poor left ventricular systolic function (11.9% v
5.5%; p0.001), three vessel coronary artery disease (19.4% v 9.2%; p0.001), left main
stem disease (8.0% v 3.2%; p0.001), previous myocardial infarction (29.5% v 13.0%;
p0.005), peripheral vascular disease (32.4% v 23.3%; p0.001) and higher logistic
EuroSCORE (21.814.2% v 21.013.4%; p0.046). Kaplan-Meier mortality at 30 days was
6.3% (95% CI 4.3% to 7.9%) in women and 7.4% (5.6% to 9.2%) in men. At 6 months, 14.1%
(11.5% to 16.7%) and 16.6% (14.0% to 16.6%) respectively. At 1 year 21.9% (18.7% to
25.1%) and 22.4% (19.4% to 25.4%) respectively. There was no difference in mortality:
p0.331 by log-rank test; hazard ratio for women 0.911 (0.754 to 1.100). There was no
difference in device success rate (96.6% in women v 96.4% in men; p0.889) or cerebro-
vascular event rate at 30 days (3.8% v 3.7%; p0.962). However, women had significantly
more major vascular complications than men (7.5% v 4.2%; p0.004).
Conclusions: Despite a higher risk profile in males there was no difference in mortality,
procedural success or cerebrovascular event rate between genders. However, women had
almost twice the rate of major vascular complications compared with men.
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Background: Background Paravalvular regurgitation (PVR) after transcatheter aortic
valve replacement (TAVR) is associated with adverse outcomes. Studies evaluating the
utility of three-dimensional echo (3DE) are limited. We performed a retrospective analysis
using 3DE-derived annular measurements and evaluated their ability to predict PVR.
Methods: 58 TAVR patients were evaluated: 35 patients who receive a post-dilatation for
paravalvular regurgitation (PD) and 23 who did not (NoPD). Intra-procedural trans-
esophageal echocardiography was performed with both two-dimensional (2DE) and 3DE
imaging. PVR areas seen on a short axis view were measured immediately following
deployment. Pre-TAVR annular dimensions included the sagittal 2DE annular diameter
and 3DE measurements of: minimal diameter, maximal diameter, mean diameter, average
diameter and area. A cover index was calculated using these diameters. An area cover
index was also calculated using nominal areas of the THV and the 3DE.
Results: PD patients were more often male (p0.01) and had larger BSA (1.83 0.24
vs. 1.67 0.23 m2, p0.013) and a higher annular eccentricity index (13.6 5.1 vs.
8.01 5.3, p0.001). Following TAVR, PD patients had larger PVR areas immediately
following deployment (40.3 17.1 vs. 15.4 14.2mm2, p0.0001). These patients had
a lower cover index irrespective of the annular diameter used (Table). All measurements
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